Wake Forest University

1. AbbVie, Inc. $3,726,054 451 payments
2. Incyte Corporation $1,007,830 354 payments
3. Pfizer Inc. $914,027 37 payments
4. Seattle Genetics, Inc. $714,907 155 payments
5. Boston Scientific Corporation $485,602 114 payments
6. Teva Pharmaceuticals USA, Inc. $343,026 31 payments
7. Omeros Corporation $186,000 1 payment
8. Avanos Medical $92,060 22 payments
9. Boehringer Ingelheim International GmbH $91,005 12 payments
10. Boehringer Ingelheim Pharma GmbH & Co.KG $85,393 7 payments

1. A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma $965,789 53 payments
2. Molecular Mechanisms for Impaired Muscle Performance in Hfpef $785,858 12 payments
3. A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma $418,992 46 payments
4. Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma $369,406 17 payments
5. A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE) $225,906 16 payments
6. Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors $196,286 44 payments
7. A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies $190,755 40 payments
8. Empa-Kidney $176,398 19 payments
9. Simplaafy $174,284 11 payments
10. M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma $162,211 5 payments

1. Patient care $10,500 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.